Magenta Therapeutics (MGTA) Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety Jan 25, 2023 04:05PM
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety Jan 25, 2023 04:05PM
Magenta Therapeutics (MGTA) Provides Update for MGTA-117 Phase 1/2 Dose Escalation Trial Dec 20, 2022 09:00AM
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial Dec 20, 2022 09:00AM
Magenta Therapeutics (MGTA) Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates Dec 12, 2022 04:38PM
View Older Stories

Dec 12, 2022 04:30PM Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
Dec 12, 2022 08:00AM Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
Nov 3, 2022 09:01AM Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
Nov 3, 2022 09:01AM Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
Aug 17, 2022 08:03AM Magenta Therapeutics (MGTA) Appoints Michael Vasconcelles to its Board
Aug 17, 2022 08:00AM Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
Aug 4, 2022 08:00AM Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
May 16, 2022 08:00AM Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
Apr 14, 2022 08:03AM Magenta Therapeutics (MGTA) Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
Apr 14, 2022 08:00AM Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
Mar 8, 2022 08:09AM Magenta Therapeutics (MGTA) Reports Q4; Provides Recent Program Highlights
Mar 8, 2022 08:00AM Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
Mar 3, 2022 08:00AM Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
Jan 18, 2022 07:00AM Sema4 (SMFR) Acquires GeneDx from OPKO (OPK)
Jan 18, 2022 07:00AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Jan 18, 2022 07:00AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Jan 10, 2022 08:00AM Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
Jan 5, 2022 08:00AM Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
Dec 14, 2021 09:00AM Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 4, 2021 09:10AM Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
Nov 4, 2021 09:09AM Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
Oct 4, 2021 08:07AM Magenta Therapeutics (MGTA) Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
Oct 4, 2021 08:00AM Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
Sep 21, 2021 08:00AM Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
Sep 15, 2021 08:03AM Magenta Therapeutics (MGTA) Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
Sep 15, 2021 08:00AM Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
Aug 5, 2021 08:00AM Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
Aug 3, 2021 08:00AM Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
Jul 22, 2021 09:15AM Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
Jul 21, 2021 08:01AM Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS
Jul 21, 2021 08:00AM Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Jul 7, 2021 07:00AM Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
Jul 6, 2021 08:00AM Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
Jun 14, 2021 08:00AM Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
Jun 4, 2021 09:04AM Magenta Therapeutics (MGTA) Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at ASCO
Jun 4, 2021 09:00AM Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clini
Jun 3, 2021 08:00AM Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
May 14, 2021 08:00AM Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
May 12, 2021 10:04AM Magenta Therapeutics (MGTA) Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
May 12, 2021 10:00AM Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
May 12, 2021 10:00AM Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
May 6, 2021 08:00AM Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
Apr 19, 2021 08:00AM Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
Mar 25, 2021 08:00AM Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference
Mar 15, 2021 08:08AM Magenta Therapeutics (MGTA) Highlights Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at EBMT 2021 Meetings
Mar 15, 2021 08:00AM Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marr
Mar 9, 2021 08:00AM Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Mar 3, 2021 08:00AM Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
Feb 8, 2021 08:00AM Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (
Jan 11, 2021 08:15AM Magenta Therapeutics (MGTA) Highlights Recent Progress and Expected Timing of 2021 Milestones
View Older Stories